---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-169038"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2023-06-16T23:59:59+00:00"
generated_at: "2026-06-13T22:41:34.507635+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Viridian shareholders approve 2M share increase to 2016 Equity Plan at annual meeting

## Summary
- Stockholders approved amendment to 2016 Equity Incentive Plan, increasing share reserve by 2,000,000 shares.
- Elected Tomas Kiselak and Jennifer K. Moses as Class II directors to serve until 2026.
- Ratified KPMG as independent auditor for 2023 with 39,588,463 votes for.
- Advisory vote on NEO compensation passed with 22,946,964 for and 12,351,317 against.
- Total shares outstanding as of record date: 43,108,897.

## SEC filing metadata
- accession: 0001193125-23-169038
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2023-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312523169038/0001193125-23-169038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312523169038/d521711d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-169038
- JSON: https://secwatch.observer/filing/0001193125-23-169038.json
- Plain text: https://secwatch.observer/filing/0001193125-23-169038.txt

## Key facts
- Shareholder Votes
  Viridian Therapeutics, Inc.\DE shareholders approved Election of the two Class II director nominees to serve until the 2026 Annual Meeting of Stockholders.
  - Proposal: director election
  - Outcome: passed
  source text: 1. Election of the two Class II director nominees to serve until the 2026 Annual Meeting of Stockholders: For Withheld Broker Non-Votes Tomas Kiselak 26,435,249 8,884,876 4,287,967 Jennifer K. Moses 34,979,960 340,165 4,287,967
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312523169038/0001193125-23-169038-index.htm
- Shareholder Votes
  Viridian Therapeutics, Inc.\DE shareholders approved Approval of a further amendment and restatement of the Company’s Amended and Restated 2016 Equity Incentive Plan, including an increase by 2,000,000 of the shares reserved for issuance thereunder.
  - Proposal: equity plan
  - Outcome: passed
  source text: 4. Approval of a further amendment and restatement of the Company’s Amended and Restated 2016 Equity Incentive Plan, including an increase by 2,000,000 of the shares reserved for issuance thereunder: For Against Abstentions Broker Non-Votes 22,896,437 12,404,022 19,666 4,287,967
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312523169038/0001193125-23-169038-index.htm
- Shareholder Votes
  Viridian Therapeutics, Inc.\DE shareholders approved Ratification of the selection of KPMG LLP as the Company’s independent auditor for 2023.
  - Proposal: auditor ratification
  - Outcome: passed
  source text: 2. Ratification of the selection of KPMG LLP as the Company’s independent auditor for 2023: For Against Abstentions Broker Non-Votes 39,588,463 9,049 10,580 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312523169038/0001193125-23-169038-index.htm
- Shareholder Votes
  Viridian Therapeutics, Inc.\DE shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers.
  - Proposal: say on pay
  - Outcome: passed
  source text: 3. Approval, on an advisory basis, of the compensation of the Company’s named executive officers: For Against Abstentions Broker Non-Votes 22,946,964 12,351,317 21,844 4,287,967
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312523169038/0001193125-23-169038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.